García-Alvarez F, Romero M S, al-Ghanem R, Calvo M T, Cortés M, Gutiérrez M
Neurology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza.
Methods Find Exp Clin Pharmacol. 1993 Mar;15(2):95-9.
A study was made of a total of 50 patients, 36 females and 14 males, with an average age of 51.3 +/- 11.71 years (range 19-71). The group consisted of outpatients who came to the neurology clinic suffering from vascular headache or other symptomatic complaint of vascular type. In all cases, the existence of an organic neurological pathology had been considered and rejected. All patients who were smokers or suffering from hypertension were excluded, as well as those who had abnormal lipid or glucose values or who were on drug treatment for other reasons. The basal erythrocyte deformability value was determined and the patients divided into two random homogeneous groups. One of the groups was treated with nimodipine (90 mg/d) and the other with nicardipine (60 mg/d) for a period of two months. After this treatment period a further determination of the erythrocyte deformability was carried out. In the group treated with nimodipine, the erythrocyte deformability varied from 45.5 +/- 7.4 mcl/s to 50.35 +/- 12.02 mcl/s (p = 0.07123). In the group treated with nicardipine, these values varied from 45.96 +/- 7.35 mcl/s to 56.21 +/- 12.72 mcl/s (p = 0.00079). It was concluded that in both groups of patients, after two months treatment with these calcium antagonists, there was an improvement in erythrocyte deformability and, therefore, in blood fluidity, although only the nicardipine-treated group reached statistically significant levels.
对总共50名患者进行了研究,其中女性36名,男性14名,平均年龄为51.3±11.71岁(范围19 - 71岁)。该组患者为由血管性头痛或其他血管型症状性主诉前来神经科门诊就诊的门诊患者。在所有病例中,均已考虑并排除了器质性神经病理学的存在。所有吸烟者、高血压患者、血脂或血糖值异常者以及因其他原因正在接受药物治疗的患者均被排除。测定基础红细胞变形能力值后,将患者随机分为两个同质组。一组用尼莫地平(90毫克/天)治疗,另一组用尼卡地平(60毫克/天)治疗,为期两个月。在该治疗期后,再次测定红细胞变形能力。在接受尼莫地平治疗的组中,红细胞变形能力从45.5±7.4微升/秒变化至50.35±12.02微升/秒(p = 0.07123)。在接受尼卡地平治疗的组中,这些值从45.96±7.35微升/秒变化至56.21±12.72微升/秒(p = 0.00079)。得出的结论是,在两组患者中,用这些钙拮抗剂治疗两个月后,红细胞变形能力有所改善,进而血液流动性也有所改善,尽管只有接受尼卡地平治疗的组达到了统计学显著水平。